

> **PRESS RELEASE/ 30 October 2014**

Coloplast delivers strong full-year results and expects high future growth.

Revenue was up by 9% to DKK 12,428m for the 2013/14 financial year, with the EBIT margin before special items at 33%, versus 32% last year. EBIT before special items increased by 13% to reach DKK 4,147m.

“I’m very pleased with our strong full-year performance, which has helped consolidate our position as a global market leader. We grew our business by 9% overall in a market that is growing by about 5%, while also increasing our EBIT margin. In other words, our consolidated profit meets the high expectations we have for our company,” says Coloplast CEO Lars Rasmussen.

Sales growth by business area was as follows: Ostomy Care 8%, Continence Care 10%, Urology Care 9% and Wound & Skin Care 10%. Revenue increased by 6% in Europe, by 10% in Other established markets and by 24% in Emerging markets.

“We’re particularly pleased with the sales performance in our Wound & Skin Care business and with the 24% growth in Emerging markets, which was driven by strong sales in the Chinese and Brazilian markets,” says Lars Rasmussen.

Outstanding new products

“I would like to emphasise the full-year improvements we saw across the board. We’ve outperformed the market in all business areas and in all geographical regions,” says Lars Rasmussen. “During the past year, we’ve also reinforced the strong momentum of our business with the launch of some outstanding new products across our business areas, such as the New SenSura® Mio ostomy bag and the SpeediCath® Compact Eve catheter.”

For the 2014/2015 financial year, Coloplast projects revenue growth of about 9% at constant exchange rates and of 11 % in DKK, and an EBIT margin of around 34%, both at constant exchange rates and in DKK.

For further information, click [here](#) to read the full-year earnings release.

The Coloplast Annual Report for 2013/14 will be released later today. For more information, go to <http://www.coloplast.com/Investor-Relations/Annual-reports/>

Also later today, Coloplast will release its Corporate Responsibility Report for 2013/14. For more information, go to <http://www.coloplast.com/About-Coloplast/Responsibility/Policies/>.

PRESS CONTACT

Simon Mehl Augustesen
Media Relations Manager
+45 4911 3488
dksia@coloplast.com

INVESTOR RELATIONS

Ian Christensen

Vice President, Investor Relations

+45 4911 1301

dkisec@coloplast.com

Financial highlights and key ratios DKKm	2013/14 12 mdr.	2012/13 12 mdr.	Change
Revenue	12,428	11,635	7%
EBIT	3,147	3,672	(14%)
EBIT margin	25%	32%	(7 p.p.)
Special items	1,000	-	-

EBIT before special items	4,147	3,672	13%
EBIT margin before special items	33%	32%	1 p.p.

Sales performance by business area	DKKm 2013/14 12 mths.	DKKm 2012/13 12 mths.	Organic growth	Reported growth
Ostomy Care	5,091	4,849	8%	5%
Continence Care	4,438	4,081	10%	9%
Urology Care	1,199	1,124	9%	7%
Wound & Skin Care	1,700	1,581	10%	8%
Revenue	12,428	11,635	9%	7%